AiPlex^® VAS

Vasculitis (VAS) Microarray Solution for the MosaiQ Platform.

Designed to provide comprehensive vasculitis diagnostic insights & workflow efficiency.

Automimmune vasculitis

Autoimmune vasculitis (VAS) causes inflammation of blood vessel walls, potentially leading to organ and tissue damage. Affected vessel type (size), organ involvement and clinical symptoms depend on various types. While its exact cause is often unknown, vasculitis can lead to life-threatening complications.¹

Current diagnostic tests include antibodies against Anti–MPO (Anti-Myeloperoxidase), Anti-PR3 (Anti-Proteinase 3) and ANCA in IFA (Anti-Neutrophil Cytoplasmic Antibodies), as well as Anti-GBM (Anti-Glomerular Basement Membrane)^2-5. Early diagnosis is crucial to prevent irreversible tissue damage and start appropriate treatment as soon as possible.^5-7

MPO

IgG

PR3

IgG

The two main types of ANCA are usually anti-PR3 and anti-MPO linked to ANCA-Associated Vasculitis (AAV):
Granulomatosis with polyangiitis (GPA)
Microscopic polyangiitis (MPA)
Eosinophilic granulomatosis with polyangiitis (EGPA)^2-4

GBM

IgG

Anti-GBM antibodies are associated with Anti-GBM disease (previously named Goodpasture’s disease) that can also be detected using MosaiQ.⁵

Fast, Easy, Comprehensive

AliveDx planar microarray supporting vasculitis diagnosis, AiPlex VAS, is designed to deliver rapid in-vitro test results, helping to reduce the time to results for patients. The MosaiQ solution supports the potential urgency of these tests, combining multiple results in one single test with no calibration required.

Designed to provide comprehensive Autoimmune Vasculitis diagnostic insights and workflow efficiency

The AiPlex VAS microarray contains key markers recommended by guidelines such as, EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update.⁵

Multiple insights in one report with only 10µl patient sample. One microarray provides up to 3 individual results.
Saves valuable time while avoiding human errors with a standardized master curve embedded into RFID^* tags, included with all reagents and microarrays.
Reduces hands-on time and storage space with ready for use, concentrated onboard reagents and buffers.

AiPlex VAS for the MosaiQ platform is designed to help reduce time-to-diagnosis for patients with Autoimmune Vasculitis

Simple Workflow

Patients sample in, result out in one single step
QC and calibration embedded

Fast Results

Use the STAT position to manage priority urgent samples
One low-volume sample tube for multiple tests

Actionable Insights

Panels help streamline clinical decision-making for physicians
Comprehensive panels simplify complex testing pathways

Learn more about our MosaiQ solution and our menu:

MosaiQ LumiQ AiPlex CTDplus AIPLEX CD ALLERGYPLEX COMBO

How can the MosaiQ AiPlex VAS assay benefit your lab?

1. Treppo E et al. Systemic vasculitis: one year in review 2024. Clin Exp Rheumatol. 2024;42(4):771-781.
2. Robson JC et al. 2022 ACR/EULAR GPA Classification Criteria. Ann Rheum Dis. 2022;81(3):315–320.
3. Suppiah R et al. 2022 ACR/EULAR MPA Classification Criteria. Ann Rheum Dis. 2022;81(3):321-326.
4. Grayson PC et al. 2022 ACR/EULAR EGPA Classification Criteria. Ann Rheum Dis. 2022;81(3):309-314.
5. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1-S276.
6. Ntatsaki E et al. BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology (Oxford). 2014;53(12):2306-9.
7. Hellmich B et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2024;83(1):30-47.
* Radio Frequency Identification.

© AliveDx Suisse SA, 2025. The AliveDx logo, AliveDx, MosaiQ AiPlex, AiPlex and MosaiQ are trademarks or registered trademarks of AliveDx group companies in various jurisdictions. Menus and capabilities are subject to change. Not all methods may be available in all territories subject to clearance in other territories.

AiPlex® VAS